Sign up to save your podcasts
Or
Share Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
View all episodes
By Dr. Neil Love
4.4
6262 ratings
Prof Francois-Clement Bidard from Institut Curie in Paris and Dr Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta discuss improving the outcomes of first-line endocrine-based therapy for patients with HR-positive, HER2-negative metastatic breast cancer.
More shows like Breast Cancer Update
View all
JAMA Editors' Summary
138 Listeners
NEJM This Week
323 Listeners
JAMA Clinical Reviews
498 Listeners
Lung Cancer Update
30 Listeners
Hematologic Oncology Update
76 Listeners
Prostate Cancer Update
14 Listeners
Gastrointestinal Cancer Update
17 Listeners
Gynecologic Oncology Update
12 Listeners
Dermatologic Oncology Update
0 Listeners
Research To Practice | Oncology Videos
121 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
294 Listeners
The Curbsiders Internal Medicine Podcast
3,361 Listeners
The ONS Podcast
205 Listeners
The Clinical Problem Solvers
515 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners
Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing
0 Listeners